Statin-Associated Polymyositis Following Omeprazole Treatment

被引:15
作者
Kanth, Rajan [1 ]
Shah, Milind [2 ]
Flores, Rafael [3 ]
机构
[1] Marshfield Clin Fdn Med Res & Educ, Dept Internal Med, 1000 North Oak Ave, Marshfield, WI 54449 USA
[2] Marshfield Clin Fdn Med Res & Educ, Dept Cardiol, Marshfield, WI USA
[3] Marshfield Clin Fdn Med Res & Educ, Dept Lab Pathol, Marshfield, WI USA
关键词
Autoimmune; Myopathy; Statins;
D O I
10.3121/cmr.2012.1110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Statins are an extensively used class of drugs, and myopathy is an uncommon, but well-described side effect of statin therapy. Inflammatory myopathies, including polymyositis, dermatomyositis, and necrotizing autoimmune myopathy, are even more rare, but debilitating, side effects of statin therapy that are characterized by the persistence of symptoms even after discontinuation of the drug. It is important to differentiate statin-associated inflammatory myopathies from other self-limited myopathies, as the disease often requires multiple immunosuppressive therapies. Drug interactions increase the risk of statin-associated toxic myopathy, but no risk factors for statin-associated inflammatory myopathies have been established. Here we describe the case of a man, age 59 years, who had been treated with a combination of atorvastatin and gemfibrozil for approximately 5 years and developed polymyositis after treatment with omeprazole for 7 months. Symptoms did not resolve after discontinuation of the atorvastatin, gemfibrozil, and omeprazole. The patient was treated with prednisone and methotrexate followed by intravenous immunoglobulin, which resulted in normalization of creatinine kinase levels and resolution of symptoms after 14 weeks. It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only.
引用
收藏
页码:91 / 95
页数:5
相关论文
共 24 条
  • [1] [Anonymous], 2011, US MED US REV 2010 A
  • [2] HMG-CoA reductase inhibitors and P-glycoprotein modulation
    Bogman, K
    Peyer, AK
    Török, M
    Küsters, E
    Drewe, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) : 1183 - 1192
  • [3] Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
    Boyd, RA
    Stern, RH
    Stewart, BH
    Wu, XC
    Reyner, EL
    Zegarac, EA
    Randinitis, EJ
    Whitfield, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) : 91 - 98
  • [4] Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    Clark, DWJ
    Strandell, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 473 - 479
  • [5] Inflammatory myopathies: management of steroid resistance
    Dalakas, Marinos C.
    [J]. CURRENT OPINION IN NEUROLOGY, 2011, 24 (05) : 457 - 462
  • [6] EVIDENCE OF PLASMA COQ10-LOWERING EFFECT BY HMG-COA REDUCTASE INHIBITORS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    GHIRLANDA, G
    ORADEI, A
    MANTO, A
    LIPPA, S
    UCCIOLI, L
    CAPUTO, S
    GRECO, AV
    LITTARRU, GP
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (03) : 226 - 229
  • [7] IMMUNE-MEDIATED NECROTIZING MYOPATHY ASSOCIATED WITH STATINS
    Grable-Esposito, Phyllis
    Katzberg, Hans D.
    Greenberg, Steven A.
    Srinivasan, Jayashri
    Katz, Jonathan
    Amato, Anthony A.
    [J]. MUSCLE & NERVE, 2010, 41 (02) : 185 - 190
  • [8] GRUNDY SM, 1988, NEW ENGL J MED, V319, P24
  • [9] Outcomes in 45 patients with statin-associated myopathy
    Hansen, KE
    Hildebrand, JP
    Ferguson, EE
    Stein, JH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (22) : 2671 - 2676
  • [10] Myopathy with statin-fibrate combination therapy: clinical considerations
    Jacobson, Terry A.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (09) : 507 - 518